AOM: Conceptualization, Writing—original draft, Writing—review & editing. OHK: Conceptualization, Writing—original draft, Writing—review & editing. Both authors read and approved the submitted version.
Conflicts of interest
Oliver H. Krämer declares the patents WO2019/034538, WO2016/020369A1, WO2004/027418, and advisory work for BASF Ludwigshafen, Germany. BASF has not promoted, sponsored, or supported this study in any way, and its products are not discussed in this publication. Oliver H. Krämer, who is the Guest Editor of Exploration of Targeted Anti-tumor Therapy, had no involvement in the decision-making or the review process of this manuscript. The other author declares no conflicts of interest.
Ethical approval
Not applicable.
Consent to participate
Not applicable.
Consent to publication
Not applicable.
Availability of data and materials
All data supporting the findings of this review are included within the article and its references. Additional data on HEMAP can be found in [31].
Funding
Work done in the group of O.H.K. is funded by the DFG grant KR2291/12-2, DFG-project number 445785155; KR2291/14-1, DFG-project number 469954457; KR2291/15-1, DFG-project number 495271833; KR2291/16-1, DFG-project number 496927074; KR2291/17-1, DFG-project number 502534123; KR 2291/18-1, DFG-project number 528202295; DFG-project number 393547839 - SFB 1361, sub-project 11; the Walter Schulz Stiftung; the Brigitte und Dr. Konstanze Wegener-Stiftung (project 110); the Deutsche José Carreras Leukämie-Stiftung (project DJCLS 09 R/204); the H.W. & J. Hector Stiftung (project M 2419); and the Dr. Werner Jackstädt-Stiftung. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Stienstra R, Netea-Maier RT, Riksen NP, Joosten LAB, Netea MG. Specific and Complex Reprogramming of Cellular Metabolism in Myeloid Cells during Innate Immune Responses.Cell Metab. 2017;26:142–56. [DOI] [PubMed]
Al-Horani RA. Cancer Metabolism and Its Historical & Molecular Foundations: An Overview.Drugs Drug Candidates. 2026;5:17. [DOI] [PubMed] [PMC]
Dunphy G, Adán-Barrientos I, Fernández-Delgado I, Villarroya-Beltri C, Heras-Murillo I, Moya-Ruiz E, et al. A type I interferon-mitochondrial axis regulates efferocytosis and interferon-stimulated gene induction in macrophages.Immunity. 2026;59:306–21.e7. [DOI] [PubMed] [PMC]
Krieg AM. New insights into the role of IFN-α/β and TLR7/8/9 in cancer immunotherapy and systemic autoimmunity.J ImmunoTher Cancer. 2025;13:e012165. [DOI] [PubMed] [PMC]
Kasat D, Hidalgo S, Wang L, Bui JD, Dosset M. Interferons as therapeutic orchestrators of cancer stem cell plasticity and therapy response.Cytokine Growth Factor Rev. 2026;87:102–12. [DOI] [PubMed]
Tecalco-Cruz AC, Zepeda-Cervantes J. Protein ISGylation: a posttranslational modification with implications for malignant neoplasms.Explor Target Antitumor Ther. 2023;4:699–715. [DOI] [PubMed] [PMC]
Feng X, Qiao Y, Cui S. When ISG15 is involved in inflammation.Front Immunol. 2026;17:1775143. [DOI] [PubMed] [PMC]
Yuan Y, Qin H, Li H, Shi W, Bao L, Xu S, et al. The Functional Roles of ISG15/ISGylation in Cancer.Molecules. 2023;28:1337. [DOI] [PubMed] [PMC]
Gupta AK, Wu J, Das P, Sharma R, Das S, Han K, et al. ISG15 orchestrates dynamic crosstalk between mitochondrial fat oxidation and type 1 interferon in myeloid cells.bioRxiv 2026.01.19.700051 [Preprint]. 2026 [cited 2026 Mar 19]. Available from: https://doi.org/10.64898/2026.01.19.700051
Quan Q, Wu N, Luo YH, Tang YJ, Liu YZ, Huang XC, et al. Global Transmission, Prevention, Control, and Treatment of Mpox Virus in 2025: A Comprehensive Review from Infection Mechanisms to Vaccine Development.Vaccines. 2025;13:1071. [DOI] [PubMed] [PMC]
Wang X, Shi X, Liao S, Su T, Gu Y, Zhang H, et al. Multidimensional effects of genetic mechanisms in cancer occurrence, development and treatment.Cancer Genet. 2026;304-305:58–75. [DOI] [PubMed]
Haikarainen T, Virtanen AT, Cravatt BF, Silvennoinen O. Pharmacological targeting of the JAK–STAT pathway: new concepts and emerging indications.Nat Rev Drug Discov. 2026;25:268–89. [DOI]
Mustafa AM, Krämer OH. Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer.Pharmacol Rev. 2023;75:35–61. [DOI] [PubMed]
Baldanta S, Fernández-Escobar M, Acín-Perez R, Albert M, Camafeita E, Jorge I, et al. ISG15 governs mitochondrial function in macrophages following vaccinia virus infection.PLOS Pathog. 2017;13:e1006651. [DOI] [PubMed] [PMC]
Palma FR, Gantner BN, Sakiyama MJ, Kayzuka C, Shukla S, Lacchini R, et al. ROS production by mitochondria: function or dysfunction?Oncogene. 2023;43:295–303. [DOI] [PubMed]
Guerra S, Cáceres A, Knobeloch KP, Horak I, Esteban M. Vaccinia Virus E3 Protein Prevents the Antiviral Action of ISG15.PLoS Pathog. 2008;4:e1000096. [DOI] [PubMed] [PMC]
Bécares M, Albert M, Tárrega C, Coloma R, Falqui M, Luhmann EK, et al. ISG15 Is Required for the Dissemination of Vaccinia Virus Extracellular Virions.Microbiol Spectr. 2023;11:e0450822. [DOI] [PubMed] [PMC]
Zhao C, Sridharan H, Chen R, Baker DP, Wang S, Krug RM. Influenza B virus non-structural protein 1 counteracts ISG15 antiviral activity by sequestering ISGylated viral proteins.Nat Commun. 2016;7:12754. [DOI] [PubMed] [PMC]
Yu SS, Tang RC, Zhang A, Geng S, Yu H, Zhang Y, et al. Deacetylase Sirtuin 1 mitigates type I IFN- and type II IFN-induced signaling and antiviral immunity.J Virol. 2024;98:e0008824. [DOI] [PubMed] [PMC]
Hansen BK, Gupta R, Baldus L, Lyon D, Narita T, Lammers M, et al. Analysis of human acetylation stoichiometry defines mechanistic constraints on protein regulation.Nat Commun. 2019;10:1055. [DOI] [PubMed] [PMC]
Mustafa AM, Petrosino G, Fischer MA, Schnöder TM, Gül D, Zeyn Y, et al. The deacetylases HDAC1/HDAC2 control JAK2V617F-STAT signaling through the ubiquitin ligase SIAH2.Signal Transduct Target Ther. 2025;10:275. [DOI] [PubMed] [PMC]
Tigu AB, Ivancuta A, Uhl A, Sabo AC, Nistor M, Mureșan XM, et al. Epigenetic Therapies in Melanoma—Targeting DNA Methylation and Histone Modification.Biomedicines. 2025;13:1188. [DOI] [PubMed] [PMC]
Mazziotta C, Lanzillotti C, Gafà R, Touzé A, Durand MA, Martini F, et al. The Role of Histone Post-Translational Modifications in Merkel Cell Carcinoma.Front Oncol. 2022;12:832047. [DOI] [PubMed] [PMC]
Ma Y, Kemp SS, Yang X, Wu MH, Yuan SY. Cellular mechanisms underlying the impairment of macrophage efferocytosis.Immunol Lett. 2023;254:41–53. [DOI] [PubMed] [PMC]
Dawson A, Zarou MM, Prasad B, Bittencourt-Silvestre J, Zerbst D, Himonas E, et al. Leukaemia exposure alters the transcriptional profile and function of BCR: ABL1 negative macrophages in the bone marrow niche.Nat Commun. 2024;15:1090. [DOI] [PubMed] [PMC]
Cruz Cruz J, Allison KC, Page LS, Jenkins AJ, Wang X, Earp HS, et al. Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment.Front Immunol. 2023;14:1146721. [DOI] [PubMed] [PMC]
Zhong F, Yao F, Bai Q, Liu J, Li X, Huang B, et al. A novel molecular classification based on efferocytosis-related genes for predicting clinical outcome and treatment response in acute myeloid leukemia.Inflamm Res. 2024;73:1889–902. [DOI] [PubMed]
Fan JB, Miyauchi-Ishida S, Arimoto K, Liu D, Yan M, Liu CW, et al. Type I IFN induces protein ISGylation to enhance cytokine expression and augments colonic inflammation.Proc Natl Acad Sci. 2015;112:14313–8. [DOI] [PubMed] [PMC]
Malik MNH, Waqas SF, Zeitvogel J, Cheng J, Geffers R, Gouda ZA, et al. Congenital deficiency reveals critical role of ISG15 in skin homeostasis.J Clin Investig. 2022;132:e132. [DOI] [PubMed] [PMC]
Zhao C, Collins MN, Hsiang TY, Krug RM. Interferon-induced ISG15 pathway: an ongoing virus–host battle.Trends Microbiol. 2013;21:181–6. [DOI] [PubMed] [PMC]
Pölönen P, Mehtonen J, Lin J, Liuksiala T, Häyrynen S, Teppo S, et al. Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies.Cancer Res. 2019;15:2466–79. [DOI] [PubMed]
